Celia Huber joins AMN Healthcare’s board of directors

DALLAS - AMN Healthcare (NYSE:AMN) announced the election of Celia Huber to its Board of Directors during its annual shareholders meeting on May 2, 2025. The healthcare staffing company, currently valued at $811 million, has seen its shares decline over 60% in the past year. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.

Huber, a Senior Partner at McKinsey & Company who leads the firm’s Board Services Practice in North America, brings more than 30 years of experience advising healthcare systems, payors and companies on strategy, risk and performance.

In her current role at McKinsey, Huber counsels Fortune 500 boards on governance, succession planning and organizational transformation. Her career has focused on advising healthcare organizations on strategy, merger integration and navigating risks in the healthcare landscape.

"Celia brings invaluable insight and leadership grounded in a career focused on governance, innovative partnerships and implementing new operating models successfully," said Cary Grace, President and CEO of AMN Healthcare, according to the company’s press release.

Huber currently serves on the board of the AltaMed Foundation and is a member of the Executive Committee of the California Business Roundtable. Her previous board experience includes Citizens United for Research in Epilepsy and Make-A-Wish Greater Pennsylvania and West Virginia, where she served as Vice Chair.

She holds an MBA from Stanford University and a bachelor’s degree in finance from the University of Texas.

AMN Healthcare describes itself as a provider of total talent solutions for healthcare organizations across the United States. Get deeper insights into AMN Healthcare’s financial health, growth prospects, and 6 additional exclusive ProTips with a subscription to InvestingPro.

In other recent news, AMN Healthcare reported its Q1 2025 financial results, revealing revenue of $690 million, which surpassed the high-end guidance by 10%. Despite a year-over-year decline, the company posted an adjusted EPS of $0.45, exceeding market expectations. Additionally, AMN Healthcare achieved a debt reduction of $60 million, showcasing its focus on financial management. However, Moody’s Ratings downgraded AMN Healthcare’s corporate family rating to Ba3 from Ba2, citing deteriorating credit metrics and a structural decline in revenues. The outlook was revised to negative due to expected rising financial leverage and declining sales. The company maintains strong liquidity, with $56 million in cash and $580 million available under its revolving credit facility. AMN Healthcare’s strategic focus on innovation and operational efficiency contributed to securing five new MSP and vendor-neutral contracts. Despite challenges, the company continues to invest in technology and operational improvements to enhance service delivery.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.